Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO3QAZ)

Drug Name

DNL310 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Mucopolysaccharidosis II	5C56.31	Phase 2/3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Iduronate 2-sulfatase (IDS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Idursulfase	DM30SXV	Hunter syndrome	5C56.31	Approved	[3]
Recombinant human iduronate-2-sulfatase	DMOWQAF	Hunter syndrome	5C56.31	Phase 3	[4]
RGX-121	DMU3PD7	Mucopolysaccharidosis	5C56.3	Phase 1/2	[5]
SB-913	DM98YFK	Mucopolysaccharidosis	5C56.3	Phase 1/2	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT05371613) A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Denali
3	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
4	The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II. PLoS One. 2014 Jan 13;9(1):e85074.
5	Clinical pipeline report, company report or official report of REGENXBIO.
6	ClinicalTrials.gov (NCT03041324) Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II. U.S. National Institutes of Health.